Abstract
A total of 66 patients treated with linezolid for more than 4 days between May 2006 and June 2014 in our hospital were investigated. Thrombocytopenia was observed in 31 patients (47.0%). The 66 patients were divided into two groups, with and without development of thrombocytopenia. The following objective variables were considered as risk factors for thrombocytopenia after linezolid administration: age, creatinine clearance (CCr), daily dosage of linezolid, duration of administration of linezolid before administration of platelets, albumen value, alanine aminotransferase value, aspartic aminotransferase value, and C-reactive protein value. Univariate analysis found significant correlation with CCr and duration of administration of linezolid. Multivariate analysis found significant correlation with CCr and duration of administration of linezolid. Therefore, CCr and duration of administration of linezolid are risk factors for thrombocytopenia. Renal function of the patients should be evaluated before administration of linezolid, and the duration of administration of linezolid should be minimized.
